Exact(5)
Lastly, we discuss the current status of clinical therapies both in development and those progressed to clinical trial specifically targeting pathologic EMTs including small molecule inhibitors, non-coding RNAs, exogenous co-factors, and adjunctive therapies to current chemotherapeutics.
Persistent islet autoantibodies developed in 169 subjects, and 55 of those progressed to diabetes.
Patients were followed for a median of 18 (range 1 19) years; 39 progressed to microalbuminuria, 8 of those progressed further to macroalbuminuria, and 24 died.
There were 57 participants who developed confirmed macroalbuminuria (≥300 μg/mg creatinine), and one-third (12) of those progressed to proteinuria (≥1,000 μg/mg creatinine).
During a median follow-up of 7.0 years, 169 children developed persistent islet autoantibodies (one or more autoantibody on at least two consecutive visits), and 55 of those progressed to diabetes.
Similar(55)
d Personalized – the learning environment can provide personalized assignments and/or formative feedback just when needed to help struggling learners as well as those progressing rapidly.
However, those progressing to fibrosis were more likely to be on protease inhibitor-based cART at baseline than those not progressing to fibrosis [ n = 47 (82%) vs. 151 (65%), respectively].
Hence, we specified a rate out of the primary stage, P, and a proportion to represent those progressing directly from primary infection to active disease.
There seems to be little doubt that T-cell responses in patients clearing cervical HPV infection are different from those progressing to cervical cancer.
The length of the disease free interval categorises patients into platinum-sensitive (those progressing 6 months or more after completion of first line platinum agents) and platinum refractory (those progressing on or within 6 months after completion of first line platinum agents).
Table 1 shows the characteristics of those who progressed to disease versus those who did not.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com